

TOPIC	DISCUSSION AND FINDINGS	RECOMMENDATION	FOLLOW-UP/ACTION
Call to Order 4:37 PM	The following members were present on the attached sign-in roster.	A quorum was present and the meeting was called to order.	None.
<b>Introduction(s)</b>			
Rojean Williams, Clinical Dietician	Presented the 2021 Diet Manual and KDOQI Guidelines Update to all MEC members for review.	None	The Guideline updates will be routed for signature.
<b>Public Comments</b>			
	None		None
<b>Minutes</b>			
Meeting Minutes	Approval of October 4, 2021 MEC minutes.	None	Motion to approve October 4, 2021 MEC meeting minutes 1 <sup>st</sup> Motion: Dr. Jennifer Dorce-Medard 2 <sup>nd</sup> Motion: Dr. Luis Perezalonso All approved
<b>Old Business</b>			
	None	None	None
<b>New Business</b>			
(2) Formulary Requests	Hydrocortisone Tabs – 10 mg Lidocaine – 4% Injectable	None	Motion to approve (2) Formulary Requests 1 <sup>st</sup> Motion: Dr. Julie Pass 2 <sup>nd</sup> Motion: Dr. Jennifer Dorce-Medard All approved
<b>Report</b>			
Treasurer Report	<b>Amount in PNC account: [\$ 99,002.21]</b> Dr. Dawkins met with the accountant. No paperwork was ever filed with IRS for the past 3 years and right now we are considered a <b>for</b> profit organization. We need to file back paperwork.	File for not-for-profit corp with accountant.	Motion to approve File for not-for profit corp with accountant 1 <sup>st</sup> Motion: Dr. Jennifer Dorce-Medard 2 <sup>nd</sup> Motion: Dr. Julie Pass

TOPIC	DISCUSSION AND FINDINGS	RECOMMENDATION	FOLLOW-UP/ACTION
<b>Committee Reports</b>			All approved
Pharmacy Report	<p><b>New Business:</b>  <b>Pharmacy Updates/Reminders -</b>                      Annual Inventory: October 1 2021</p> <ul style="list-style-type: none"> <li>• FY 2021: \$639,155.24 vs FY 2020: \$380,148.15</li> <li>• Increase in medication purchases due to COVID admissions: Remdesivir, antimicrobials</li> </ul> <p>Pharmacy Board Inspection:</p> <ul style="list-style-type: none"> <li>• October 18</li> <li>• No findings for Class II &amp; III Institutional Inspection</li> <li>• Sterile Compounding Inspection: Corrective Action Plan in progress for submission to BOP</li> </ul> <p>P&amp;P Updates:</p> <ul style="list-style-type: none"> <li>• Policies and Procedures are currently under review</li> </ul> <p>Formulary Changes:</p> <p>Formulary Additions –</p> <ul style="list-style-type: none"> <li>• Lidocaine 4% for intractable cough via inhalation</li> <li>• Hydrocortisone Tablets for Adrenal Insufficiency</li> </ul> <p>Other Requests:</p> <p>Regen COV -</p> <ul style="list-style-type: none"> <li>• Requested by OB for COVID + patients</li> <li>• Request submitted to the state: awaiting reply</li> </ul>	None	

TOPIC	DISCUSSION AND FINDINGS	RECOMMENDATION	FOLLOW-UP/ACTION
	<p><b>Old Business:</b></p> <ul style="list-style-type: none"> <li>Baricitinib order set released to PROD and medication is in stock for ordering.</li> </ul> <p>Insulin vials now in Pyxis:</p> <ul style="list-style-type: none"> <li>Education on Cornerstone for hospital staff</li> <li>Will monitor for completion with Kim</li> </ul> <p><b>Medication Variances:</b></p> <ul style="list-style-type: none"> <li>One wrong patient ID</li> <li>One Pyxis miss fill</li> </ul> <p><b>Antimicrobial Stewardship:</b></p> <ol style="list-style-type: none"> <li>44 antimicrobial orders were reviewed for interventions and recommendations were made for 26.</li> <li>Duplicate therapy is the highest trending intervention in September, followed by pharmacokinetic monitoring.</li> <li>Antimicrobial purchases are meeting goal, and decreased in September. Remdesivir purchases decreased in September as the inpatient admissions for COVID-19 declines. (30patients with orders in September vs 75 patients with orders in August)</li> <li>Days of therapy and length decreased from last month due to decrease use of antimicrobials and in COVID-19 admissions.</li> </ol> <p><b>ISMP Safety</b></p> <ul style="list-style-type: none"> <li>Challenges with requiring five characters during ADC drug searches via override.</li> </ul>		

TOPIC	DISCUSSION AND FINDINGS	RECOMMENDATION	FOLLOW-UP/ACTION
	<ul style="list-style-type: none"> <li>Potential for inaccurate medication history data.</li> <li>FDA communication on the accuracy of ENFit low dose tip syringes.</li> </ul> <p><b>Barcode Medication Administration Report</b></p> <ul style="list-style-type: none"> <li>The Barcode Administration Scanning Goal is based on Leapfrog BCMA standards is 95% for combined medication and patient scanning.</li> <li>All departments showed an improvement compared to August’s report with a decrease in Med Surg, Pediatrics and PCU.</li> <li>This report will be phased out in EPIC, since it is not used by MHS, and a more accurate report will be used going forward.</li> </ul> <p><b>Scanned Flushes Report</b></p> <ul style="list-style-type: none"> <li>Flushes scanned on administration have remained consistent since last month.</li> </ul>		
<b>Department Reports</b>			
Family Residency Report	Nothing to report	None	None
Delinquent Medical Records	All MEC members received the Delinquent Medical Records report for September 2021. Deficiencies – 242 and at 15%.	None	Dr. Medard and RoseAnn will meet tomorrow for discussion.
Emergency Department Report	All MEC members received the ED Report for the month of September 2021. Dr. Perezalonso reported the ER seen 1,262. Transfers – 63, compared to 58 last year. Hospitalized – 195; AMA	None	None

TOPIC	DISCUSSION AND FINDINGS	RECOMMENDATION	FOLLOW-UP/ACTION
	– 15. There were 2 Mid-levels and 1 new Physician hired.		
Radiology Report	All MEC members received the Radiology Report for September 2021.	None	None
Surgery Services Report	All MEC members received the Surgical Report for July and September 2021.	None	None
Credentialing Report	Nothing to report	None	None
Lab Report	All MEC members received the Laboratory report for September 2021. Wastage: 2 units PRBC – expired on stock; 19 units of plateletpheresis – expired on stock, totaling \$12,475.43 for September. YTD Total - \$85,251.11.	More information is needed on the High Sensitivity Cardiac Troponin. Dr. Perezalonso, Dr. Bolton, Dr. Gunawardene and Dr. Henriquez will meet on the 15 <sup>th</sup> for further discussion.	Will report at the next MEC meeting.
OB Services Report	All MEC members received the OB report for September 2021: 9 deliveries; 5 vaginals, and 4 C-sections.	None	None
Community Liaison Report	Nothing to report	None	None
Pediatric Report	All MEC members received the Pediatric report for September 2021: 9 babies delivered.	None	None
Associate CMO Report	<p>FPPE/OPPE Policy &amp; Procedure</p> <p>All MEC members received the Associate CMO Report for September 2021.</p> <p><b>New Business:</b></p>	None	<p>Motion to approve FPPE/OPPE Policy &amp; Procedure</p> <p>1<sup>st</sup> Motion: Dr. Julie Pass</p> <p>2<sup>nd</sup> Motion: Dr. Luis Perezalonso</p> <p>All approved</p>

TOPIC	DISCUSSION AND FINDINGS	RECOMMENDATION	FOLLOW-UP/ACTION
	<ul style="list-style-type: none"> <li>Boys and Girls Club (Wellington) – Charitable contribution for annual fundraiser by Dr. Ferwerda. If you would like to consider or to donate individually, please contact her.</li> </ul> <p><b>PPEC (Professional Excellence Committee) meeting:</b></p> <ul style="list-style-type: none"> <li>Dr. Pass and Dr. Medard met with OB provider on 10/18/21 and notified her of her peer review results and notified of ongoing monitoring.</li> <li>No new cases</li> <li>Token of appreciation to staff from Medical Staff? Dr. Pass suggested a Plaque for Dr. Pena in the Pediatric Department. Host a memorial in his honor, invite his family. Email Dr. Medard with suggestions and ideas.</li> </ul>		
Quality Report	Nothing to report	None	None
Director of Nursing Report	Nothing to report	None	None
Risk Management	<p>All MEC members received a copy of the Risk Management Dashboard – Quarter 3 - September 2021.</p> <p>EPIC: Falls procedure being revised; AMA Form – Inpatient, in EPIC. Ventilator Associated Events.</p> <p>IV Infiltrations-recent increase. There were 49 incidents for this quarter. Good catch – 1. Top 5:</p>	None	None

TOPIC	DISCUSSION AND FINDINGS	RECOMMENDATION	FOLLOW-UP/ACTION
	AMA, Infection Control, Lab, IV/Blood and Admission process.		
Associate VP Report	Nothing to report	None	None
Adjournment	Meeting adjourned at 6:00 p.m. Next meeting December 6, 2021		

APPROVED